IN-PATIENT OUTCOMES OF PHARMACOINVASIVE REPERFUSION STRATEGY FOR ST ELEVATION MYOCARDIAL INFARCTION

Aim. To evaluate efficacy of pharmacoinvasive strategy (PCS) of treatment in ST elevation myocardial infarction (STEMI) in Rostovskaya Region, during the nearest (in-patient) period.

Material and methods. The analysis performed, of 587 STEMI patients, who were referred to Regional Vascular Center “ROKB” of Rostov-na-Donu city from hospitals of the city and neighborhoods since January 2010 till June 2015, with the aim to undergo percutaneous coronary intervention (PCI) after thrombolytic therapy (TT) as PCS reperfusion strategy. Timeline mediana from pain onset to the start of TT was 140 minutes (interquartile range: 80,5-205 min). In 36,5% cases, TT was done at prehospital stage. Timeline mediana between TT and PCI was 34 hours. The results were evaluated in the nearest (in-hospital) period by the parameters as success of TT by ST dynamics on ECG, the level of blood flow restore in infarction-related artery (IRA) by TIMI score on coronary arteriography after TT in finishing of PCI, the rate of bleedings by TIMI and combinatory parameter of major adverse cardiovasular events (death, recurrent MI, stroke, need for another revascularization of target vessel).

Results. ТТ regarded as successful in 52,5% of patients. By the results of coronary arteriography, blood flow TIMI-2/3 after TT was reached in 378 from 586 (64,5%) of patients. Stenting of coronary arteries was done in 548 among 586 (93,5%) of patients; in 25 (4,3%) of patients after TT there were no hemodynamically significant stenoses, in 13 (2,2%) patients stenting of IRA was technically impossible. Application of PCS in STEMI treatment made it to achieve TIMI-2/3 blood flow in IRA in 98,5% (577 among 586) patients. Rate of major bleedings was 1,9%. Stent thrombosis and recurrent infarctions did not happen, in-hospital mortality was 3,6%, rate of major adverse cardiovascular events — 3,7%.

Conclusion. PCS makes it to increase time parameters of reperfusion and to increase its efficacy comparing to thrombolysis in those hospitals where it is impossible to perform primary PCI to improve long-term results of PCS it is important to reduce the time “pain-needle”, and to perform coronary angiography in maximum short time after thrombolysis. Regardless that the PCS matches with the region specifics, it is important to optimize healthcare with the aim to perform primary PCI for the highest possible number of patients.

1. Boersma E, Mercado N, Poldermans D, et al. Acute myocardial infarction. Lancet 2003; 361: 847-58.

2. Ribichini F, Ferrero V, Wijns W. Reperfusion treatment of ST-elevation acute myocardial infarction. Prog Cardiovasc Dis 2004; 47: 131–57.

3. Kleinschmidt K, Brady WJ. Acute coronary syndromes: an evidence based review and outcome-optimizing guidelines for patients with and without procedural coronary intervention (PCI). Part III. Fibrinolytic therapy, procedural coronary intervention, multimodal approaches, and medical prophylaxis with low molecular weight heparins. Hospital Medicine Consensus Reports. Atlanta, GA: American Health Consultants. 2001.

4. Keeley EC, Boura JA, Grines CL. Comparison of primary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.

5. Steg PG, James SK, Atar D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-619.

6. McNamara RL, Herrin J, Bradley EH, et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol 2006; 47: 45-51.

7. Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111: 761-7.

8. Fath-Ordoubadi F, Huehns TY, Al-Mohammad A, et al. Significance of the Thrombolysis in Myocardial Infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. Am Heart J 1997; 134: 62-8.

9. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999; 100: 14-20.

10. Brodie BR, Hansen C, Stuckey TD, et al. Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol 2006; 47: 289-95.

11. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283: 2941-7.

12. De Luca G, vant Hof AW, de Boer MJ, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 2004; 25: 1009-13.

13. Shavelle DM, Rasouli ML, Frederick P, et al. Outcome in patients transferred for percutaneous coronary intervention (a National Registry of Myocardial Infarction 2/3/4 analysis). Am J Cardiol 2005; 96: 1227-32.

14. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-5.

15. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.

16. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.

17. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction— executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.

18. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-6.

19. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J 2003; 24: 94-104.

20. Pollack CV, Cohen M. Outcome-effective management of acute coronary syndromes: guidelines, protocols, and recommendations for emergency medicine practice. CEVAT Panel Reports. Atlanta, GA: American Health Consultants. 2002.

21. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92: 824-6.

22. Brodie BR, Stuckey TD, Hansen C, et al. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000; 85: 13-8.

23. De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004; 43: 1363-7.

24. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the Primary Angioplasty in Myocardial Infarction trials. Circulation. 2001; 104: 636-41.

25. Armstrong PW. WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006; 27: 1530-8.

26. Bоhmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2009; 54: 102-10.

27. Cantor WJ, Fitchett D, Borgundvaag B, et al. TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360: 2705-18.

28. Danchin N, Coste P, Ferrières J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment–elevation acute myocardial infarction. Data From the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation 2008; 118: 268-76.

29. Di Mario C, Dudek D, Piscione F, et al. CARESS-in-AMI (Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 371: 559-68.